Literature DB >> 3358462

Deficit and nondeficit forms of schizophrenia: the concept.

W T Carpenter1, D W Heinrichs, A M Wagman.   

Abstract

The authors provide a rationale for distinguishing the primary, enduring negative symptoms of schizophrenia (termed "deficit symptoms") from the more transient negative symptoms secondary to other factors. They argue that the former are more likely to provide a basis for meaningful subtyping of the schizophrenic syndrome, while the latter are more likely to respond to currently available treatments. They describe their experience in using clinical judgment based on longitudinal observations to identify deficit and nondeficit subtypes of schizophrenic patients and propose criteria for defining schizophrenia with the deficit syndrome.

Entities:  

Mesh:

Year:  1988        PMID: 3358462     DOI: 10.1176/ajp.145.5.578

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  216 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models.

Authors:  Anthony O Ahmed; Gregory P Strauss; Robert W Buchanan; Brian Kirkpatrick; William T Carpenter
Journal:  Schizophr Bull       Date:  2014-11-14       Impact factor: 9.306

3.  Chronicity reconsidered: improving person-environment fit through a consumer-run service.

Authors:  M J Chinman; R Weingarten; D Stayner; L Davidson
Journal:  Community Ment Health J       Date:  2001-06

4.  Spatio-temporal luminance contrast sensitivity and visual backward masking in schizophrenia.

Authors:  Walter L Slaghuis
Journal:  Exp Brain Res       Date:  2004-01-30       Impact factor: 1.972

5.  Active eye fixation performance in 940 young men: effects of IQ, schizotypy, anxiety and depression.

Authors:  N Smyrnis; E Kattoulas; I Evdokimidis; N C Stefanis; D Avramopoulos; G Pantes; C Theleritis; C N Stefanis
Journal:  Exp Brain Res       Date:  2003-12-19       Impact factor: 1.972

6.  [The initial dysphoric reaction (IDR) to the first dose of neuroleptics].

Authors:  B Graf Schimmelmann; M Schacht; C Perro; M Lambert
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

7.  Risk factors for psychosis: impaired social and role functioning.

Authors:  Barbara A Cornblatt; Ricardo E Carrión; Jean Addington; Larry Seidman; Elaine F Walker; Tyronne D Cannon; Kristin S Cadenhead; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Scott W Woods; Robert Heinssen; Todd Lencz
Journal:  Schizophr Bull       Date:  2011-11-10       Impact factor: 9.306

8.  Eugen Bleuler and the schizophrenias: 100 years after.

Authors:  Victor Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2011-11       Impact factor: 9.306

9.  Positive and negative symptoms in families with schizophrenia.

Authors:  A S Bassett; E J Collins; S E Nuttall; W G Honer
Journal:  Schizophr Res       Date:  1993-12       Impact factor: 4.939

10.  The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

Authors:  Ahmed A Othman; George Haig; Hana Florian; Charles Locke; Lev Gertsik; Sandeep Dutta
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.